Vabysmo (faricimab) is the only bispecific antibody registered with the Australian Registry of Therapeutic Goods for neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO).1,2
Vabysmo is listed on the Pharmaceutical Benefits Scheme (PBS) for nAMD and DMO.3
This intravitreal treatment works on two distinct pathways, specifically recognising and blocking angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF).1 After the four initial four-weekly loading doses, the frequency of ongoing injections may be extended up to every 16 weeks based on the patient’s anatomic and/or visual outcomes.1,4,5
Contact: Roche Account Manager
Please review the Product Information before prescribing, available at: roche-australia.com/productinfo/vabysmo.
Vabysmo ▼ is listed on the PBS for nAMD and DMO. Refer to PBS Schedule for full authority information.
▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.
M-AU-00002420. Prepared Mar 24.
References
- Vabysmo approved product information. Available at roche-australia.com/productinfo/vabysmo.
- Australian Government Department of Health and Aged Care. Australian Register of Therapeutic Goods (ARTG). Available at: tga.gov.au/resources/artg [accessed 11 February 2025].
- Department of Health. Pharmaceutical Benefits Scheme. Available at pbs.gov.au.
- Heier J et al. Lancet 2022. doi: 10.1016/S0140-6736(22)00010-1.
- Wykoff C, et al. Lancet 2022;399:741-755. doi: 10.1016/S0140-6736(22)00018-6.
